# A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

> **NCT06673641** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 382 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%
- **DRUG:** CABTREO Topical Gel
- **DRUG:** Placebo Control

## Key facts

- **NCT ID:** NCT06673641
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-13
- **Primary completion:** 2024-09-03
- **Final completion:** 2024-09-03
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06673641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06673641, "A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06673641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*